{"date":"2025-07-16","count":12,"source":"公開資訊觀測站（MOPS）","attribution":"引用請註明：Drugnews 事實帳本（https://drugnews.com.tw/filings/）與公開資訊觀測站原始公告","records":[{"id":"tw-7827-2025-07-16-2103-zssqmw","company_id":"7827","company":"漢康-KY創","market":"上市","industry":"生技醫療","date":"2025-07-16","time":"21:03:42","subject":"更正本公司114年5月及114年6月背書保證明細表資訊","clause":"","fact_date":"","cite_as":"公開資訊觀測站重大訊息：漢康-KY創（7827），2025-07-16 21:03，「更正本公司114年5月及114年6月背書保證明細表資訊」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6589-2025-07-16-2022-8o6k6q","company_id":"6589","company":"台康生技","market":"上市","industry":"生技醫療","date":"2025-07-16","time":"20:22:53","subject":"本公司普通股股票初次上市暨終止上櫃買賣日期","clause":"","fact_date":"","cite_as":"公開資訊觀測站重大訊息：台康生技（6589），2025-07-16 20:22，「本公司普通股股票初次上市暨終止上櫃買賣日期」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4745-2025-07-16-1842-1a9bi2a","company_id":"4745","company":"合富-KY","market":"上櫃","industry":"生技醫療","date":"2025-07-16","time":"18:42:56","subject":"公告本公司財務主管、會計主管異動","clause":"","fact_date":"","cite_as":"公開資訊觀測站重大訊息：合富-KY（4745），2025-07-16 18:42，「公告本公司財務主管、會計主管異動」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4746-2025-07-16-1824-y08ual","company_id":"4746","company":"台耀","market":"上市","industry":"生技醫療","date":"2025-07-16","time":"18:24:01","subject":"公告本公司董事長訂定現金股利除息基準日","clause":"第14款","fact_date":"2025-07-16","cite_as":"公開資訊觀測站重大訊息：台耀（4746），2025-07-16 18:24，「公告本公司董事長訂定現金股利除息基準日」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-7427-2025-07-16-1749-mlti7y","company_id":"7427","company":"華上生醫","market":"興櫃","industry":"生技醫療","date":"2025-07-16","time":"17:49:05","subject":"公告華上生醫自主開發新一代表觀免疫調控抗癌候選新藥GNTbm-38，除已先後取得美國等多國專利許可外，今日又接獲專利事務所通知，分別取得沙烏地阿拉伯及越南發明專利","clause":"第44款","fact_date":"2025-07-16","cite_as":"公開資訊觀測站重大訊息：華上生醫（7427），2025-07-16 17:49，「公告華上生醫自主開發新一代表觀免疫調控抗癌候選新藥GNTbm-38，除已先後取得美國等多國專利許可外，今日又接獲專利事務」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-7762-2025-07-16-1608-1de4yg8","company_id":"7762","company":"吉晟生","market":"興櫃","industry":"生技醫療","date":"2025-07-16","time":"16:08:04","subject":"公告本公司員工認股權憑證轉換普通股增資基準日","clause":"第44款","fact_date":"2025-07-16","cite_as":"公開資訊觀測站重大訊息：吉晟生（7762），2025-07-16 16:08，「公告本公司員工認股權憑證轉換普通股增資基準日」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-7762-2025-07-16-1607-1l248wr","company_id":"7762","company":"吉晟生","market":"興櫃","industry":"生技醫療","date":"2025-07-16","time":"16:07:18","subject":"公告本公司114年現金增資收足股款暨增資基準日","clause":"第44款","fact_date":"2025-07-16","cite_as":"公開資訊觀測站重大訊息：吉晟生（7762），2025-07-16 16:07，「公告本公司114年現金增資收足股款暨增資基準日」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6848-2025-07-16-1600-1ryuuvm","company_id":"6848","company":"拉法醫","market":"興櫃","industry":"生技醫療","date":"2025-07-16","time":"16:00:56","subject":"公告本公司董事長訂定除權基準日相關事宜","clause":"第31款","fact_date":"2025-07-16","cite_as":"公開資訊觀測站重大訊息：拉法醫（6848），2025-07-16 16:00，「公告本公司董事長訂定除權基準日相關事宜」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4107-2025-07-16-1509-100esni","company_id":"4107","company":"邦特","market":"上櫃","industry":"生技醫療","date":"2025-07-16","time":"15:09:06","subject":"公告本公司研發主管異動","clause":"第8款","fact_date":"2025-07-16","cite_as":"公開資訊觀測站重大訊息：邦特（4107），2025-07-16 15:09，「公告本公司研發主管異動」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6617-2025-07-16-1428-3wq9mu","company_id":"6617","company":"共信-KY","market":"上櫃","industry":"生技醫療","date":"2025-07-16","time":"14:28:05","subject":"代子公司共信醫藥科技股份有限公司與馬來西亞F公司正式簽訂本公司產品PTS302於馬來西亞地區之授權及經銷合約","clause":"","fact_date":"","cite_as":"公開資訊觀測站重大訊息：共信-KY（6617），2025-07-16 14:28，「代子公司共信醫藥科技股份有限公司與馬來西亞F公司正式簽訂本公司產品PTS302於馬來西亞地區之授權及經銷合約」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6617-2025-07-16-1427-1en15xg","company_id":"6617","company":"共信-KY","market":"上櫃","industry":"生技醫療","date":"2025-07-16","time":"14:27:50","subject":"代子公司共信醫藥科技股份有限公司與G公司簽訂本公司產品PTS-302於台灣地區之授權開發合作意向書","clause":"","fact_date":"","cite_as":"公開資訊觀測站重大訊息：共信-KY（6617），2025-07-16 14:27，「代子公司共信醫藥科技股份有限公司與G公司簽訂本公司產品PTS-302於台灣地區之授權開發合作意向書」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6492-2025-07-16-0628-47cv06","company_id":"6492","company":"生華科","market":"上櫃","industry":"生技醫療","date":"2025-07-16","time":"06:28:23","subject":"生華科新藥Pidnarulex(CX-5461)獲選由美國國家癌症研究所贊助五年的抗癌計畫，首個單獨用藥治療晚期實體腫瘤試驗，已啟動收案並收治第一位患者。","clause":"","fact_date":"","cite_as":"公開資訊觀測站重大訊息：生華科（6492），2025-07-16 06:28，「生華科新藥Pidnarulex(CX-5461)獲選由美國國家癌症研究所贊助五年的抗癌計畫，首個單獨用藥治療晚期實體腫瘤」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"}]}